Results 111 to 120 of about 36,987 (240)
Supplemental material, sj-docx-1-cll-10.1177_09636897241242624 for Optimization of Xenografting Methods for Generating Human Skeletal Muscle in Mice by Andrea O’Neill, Anna Llach Martinez, Amber L.
Maureen A. Kane (247626) +7 more
core +1 more source
ABSTRACT Introduction Gender‐affirming hormone therapy (GAHT) may be associated with increased cardiometabolic disease (CMD) risk. Prospective CMD risk screening is recommended, but long‐term data are needed regarding changes in CMD markers. Objectives To evaluate prospective changes in CMD risk markers during GAHT.
Louise Lehmann Christensen +7 more
wiley +1 more source
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest +15 more
wiley +1 more source
Supplemental material, sj-xls-2-cll-10.1177_09636897241231892 for The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer by Jia Han, Bowen Zhang, Senyu Zheng, Yuan Jiang, Xiaopeng Zhang and Kaiyun Mao in Cell ...
Jia Han (451925) +5 more
core +1 more source
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo +17 more
wiley +1 more source
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz +45 more
wiley +1 more source
Supplemental material, sj-xls-1-cll-10.1177_09636897241231892 for The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer by Jia Han, Bowen Zhang, Senyu Zheng, Yuan Jiang, Xiaopeng Zhang and Kaiyun Mao in Cell ...
Jia Han (451925) +5 more
core +1 more source
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo +7 more
wiley +1 more source
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source

